11C-methionine positron emission tomography for target delineation of recurrent glioblastoma in re-irradiation planning

Tanaka, Hidekazu; Yamaguchi, Takahiro; Hachiya, Kae; Miwa, Kazuhiro; Shinoda, Jun; Hayashi, Masahide; Ogawa, Shinichi; Nishibori, Hironori; Goshima, Satoshi

doi:10.1016/j.rpor.2018.04.003

Cited by 3 publications

(3 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The standard first-line treatment for glioblastoma involves a variety of modalities, including surgical resection, radiotherapy and temozolomide-adjuvant chemotherapy (6). Despite surgical resection and chemoradiation, tumors in almost all patients are likely to relapse, with a 2-year survival rate of only 26% following relapse (7). There is currently no standard and uniform management method for recurrent glioblastoma.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA‑181 inhibits glioblastoma cell growth by directly targeting CCL8

Zhai

Chen

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

MicroRNAs (miRNAs/miRs), including miR-181, are closely linked to the development and progression of glioblastoma. However, the function of miR-181 in glioblastoma has not been fully clarified. The aim of the present study was to investigate the role of miR-181 in glioblastoma. miR-181 was revealed to be downregulated in glioblastoma tissues and cell lines, and associated with poor prognosis in patients with glioblastoma. Overexpression of miR-181 inhibited glioblastoma cell proliferation, invasion and migration, arrested glioblastoma cell cycle in the G1 phase and induced glioblastoma cell apoptosis. miR-181 was demonstrated to decrease expression of C-C motif chemokine ligand 8 (CCL8) by directly interacting with its 3′-untranslated region. Overexpression of CCL8 inversely reversed the proliferation, invasion and migration-promoting effects of miR-181 in glioblastoma cells. Furthermore, CCL8 was upregulated in glioblastoma tissues and was negatively correlated with miR-181 expression. These results indicate that miR-181 is a potential molecular biomarker or therapeutic target in the clinical management of glioblastoma.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA‑181 inhibits glioblastoma cell growth by directly targeting CCL8

Zhai

Chen

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…11 C-MET also has utility in evaluating glioma patients who undergo other forms of treatment. A study found that 11 C-MET was useful in monitoring the short-term therapeutic effects of laser-induced interstitial thermotherapy (LITT) in the management of GBM patients, as a continuous decline in metabolic tumor volume indicated by 11 C-MET correlated with treatment [27]. Regarding treatment planning, this radiotracer has been used to delineate tumor extent for re-irradiation, showing uptake outside the CE-MRI enhancement region in 74% of patients [28].…”

Section: C-metmentioning

confidence: 99%

A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review

Muthukumar

Darden

Crowley

et al. 2022

IJMS

View full text Add to dashboard Cite

Humans with high-grade gliomas have a poor prognosis, with a mean survival time of just 12–18 months for patients who undergo standard-of-care tumor resection and adjuvant therapy. Currently, surgery and chemoradiotherapy serve as standard treatments for this condition, yet these can be complicated by the tumor location, growth rate and recurrence. Currently, gadolinium-based, contrast-enhanced magnetic resonance imaging (CE-MRI) serves as the predominant imaging modality for recurrent high-grade gliomas, but it faces several drawbacks, including its inability to distinguish tumor recurrence from treatment-related changes and its failure to reveal the entirety of tumor burden (de novo or recurrent) due to limitations inherent to gadolinium contrast. As such, alternative imaging modalities that can address these limitations, including positron emission tomography (PET), are worth pursuing. To this end, the identification of PET-based markers for use in imaging of recurrent high-grade gliomas is paramount. This review will highlight several PET radiotracers that have been implemented in clinical practice and provide a comparison between them to assess the efficacy of these tracers.

show abstract

“…Positron emission tomography (PET) has been used in the evaluation of brain tumors for many years (4), showing utility in several instances such as improving delineation of tumor boundaries for surgery and radiotherapy planning (5), differentiating between tumor progression and treatment-related changes (6), monitoring early/late therapy response (7), and identification of favorable biopsy sites (8). Historically, evaluation of glucose metabolic rate ( 18 F-FDG) has been used in assessing brain tumors, with sensitivity being hindered by elevated normal background uptake of 18 F-FDG, as well as increased glucose usage due to inflammatory responses potentially independent to the tumor response or growth.…”

Section: Introductionmentioning

confidence: 99%

Tumor microenvironment and fibroblast activation protein inhibitor (FAPI) PET: developments toward brain imaging

et al. 2023

View full text Add to dashboard Cite

Fibroblast activation protein (FAP) is a type-II membrane bound glycoprotein specifically expressed by activated fibroblasts almost exclusively in pathological conditions including arthritis, fibrosis and cancer. FAP is overexpressed in cancer-associated fibroblasts (CAFs) located in tumor stroma, and is known to be involved in a variety of tumor-promoting activities such as angiogenesis, proliferation, resistance to chemotherapy, extracellular matrix remodeling and immunosuppression. In most cancer types, higher FAP expression is associated with worse clinical outcomes, leading to the hypothesis that FAP activity is involved in cancer development, cancer cell migration, and cancer spread. Recently, various high selectivity FAP inhibitors (FAPIs) have been developed and subsequently used for positron emission tomography (PET) imaging of different pathologies. Considering the paucity of widely available and especially mainstream reliable radioligands in brain cancer PET imaging, and the poor survival rates of patients with certain types of brain cancer such as glioblastoma, FAPI-PET represents a major development in enabling the detection of small primary or metastatic lesions in the brain due to its biological characteristics and low background accumulation. In this work, we aim to summarize the potential avenues for use of FAPI-PET, from the basic biological processes to oncologic imaging and with a main focus on brain imaging.

show abstract

11C-methionine positron emission tomography for target delineation of recurrent glioblastoma in re-irradiation planning

Abstract: A margin of at least 5 mm around the high intensity area on T2-MRI is necessary in the target volume delineation of recurrent glioblastoma for the coverage of MET-PET findings in re-radiation therapy planning.

Cited by 3 publications

References 26 publications

MicroRNA‑181 inhibits glioblastoma cell growth by directly targeting CCL8

MicroRNA‑181 inhibits glioblastoma cell growth by directly targeting CCL8

A Comparison of PET Tracers in Recurrent High-Grade Gliomas: A Systematic Review

Tumor microenvironment and fibroblast activation protein inhibitor (FAPI) PET: developments toward brain imaging

Contact Info

Product

Resources

About